Enzymes useful for treating and methods for treating MPS-VI and cell lines for producing such enzymes recombinantly

Details for Australian Patent Application No. 2001255771 (hide)

International Classifications

Event Publications

8 January 2004 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

This application lapsed under section 142(2)(f)/See Reg. 8.3(3). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

15 January 2004 Section 223 Application Received

Biomarin Pharmaceuticals An application to extend the time from 01 Dec 2002 to 01 Oct 2003 in which to enter the National Phase has been filed . Address for service in Australia - Wray & Associates Level 4, The Quadrant 1 William Street Perth WA 6831

11 March 2004 Section 223 Application Allowed

Biomarin Pharmaceuticals The time in which to enter the National Phase has been extended to 01 Oct 2003. Address for service in Australia - Wray & Associates Level 4, The Quadrant 1 William Street Perth WA 6831

29 April 2004 Change of Name(s) of Applicant(s), Section 104

Biomarin Pharmaceuticals The name of the applicant has been changed to BioMarin Pharmaceutical Inc. 2002

31 May 2007 Application Accepted

Published as AU-B-2001255771

27 September 2007 Standard Patent Sealed

5 June 2008 Extension of Term of Standard Patents

Biomarin Pharmaceutical Inc. The earliest first regulatory approval date provided by the patentee 20 Mar 2007 For the goods NAGLAZYME galaulfase-rch

21 August 2008 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 18 Jul 2008. Address for service in Australia - Wrays Ground Floor 56 Ord Street West Perth WA 6005

22 January 2009 Extension of Term of Standard Patents

Biomarin Pharmaceutical Inc. The earliest first regulatory approval date provided by the patentee 20 Mar 2007 For the goods NAGLAZYME galaulfase-rch Address for service in Australia: Wrays Ground Floor 56 Ord Street West Perth WA 6005

11 June 2009 Extension granted

Biomarin Pharmaceutical Inc. The earliest first regulatory approval date provided by the patentee 20 Mar 2007 For the goods NAGLAZYME galaulfase-rch Extension of Term of patent pursuant to Section 77 expires on 20 Mar 2022

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.